Endocrinology and Metabolism

Won-Min Hwang (Hwang WM)

2 Articles

Clinical Study
Effects of Short-Term Exenatide Treatment on Regional Fat Distribution, Glycated Hemoglobin Levels, and Aortic Pulse Wave Velocity of Obese Type 2 Diabetes Mellitus Patients: Ju-Young Hong, Keun-Young Park, Byung-Joon Kim, Won-Min Hwang, Dong-Ho Kim, Dong-Mee Lim; Endocrinol Metab. 2016;31(1):80-85. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.80

5,882 View
51 Download
27 Web of Science
23 Crossref

Background

Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Exenatide treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of exenatide on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients.

Methods

For 1 month, 32 obese type 2 diabetes mellitus patients were administered 5 µg of exenatide twice daily. The dosage was then increased to 10 µg. Patients' height, body weight, glycated hemoglobin levels, lipid profile, pulse wave velocity (PWV), body mass index, fat mass, and muscle mass were measured by using Inbody at baseline and after 3 months of treatment.

Results

After 3 months of treatment, glycated hemoglobin levels decreased significantly (P=0.007). Triglyceride, total cholesterol, and low density lipoprotein levels decreased, while aspartate aminotransferase and alanine aminotransferase levels were no change. Body weight, and fat mass decreased significantly (P=0.002 and P=0.001, respectively), while interestingly, muscle mass did not decrease (P=0.289). In addition to, Waist-to-hip ratio and aortic PWV decreased significantly (P=0.006 and P=0.001, respectively).

Conclusion

Effects of short term exenatide use in obese type 2 diabetes mellitus with cardiometabolic high risk patients not only reduced body weight without muscle mass loss, body fat mass, and glycated hemoglobin levels but also improved aortic PWV in accordance with waist to hip ratio.

Citations

Citations to this article as recorded by

Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics
Christiana Eleojo Aruwa, Saheed Sabiu
Heliyon.2024; 10(1): e23114. CrossRef
Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial
Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, Kristian L. Funck, Esben Laugesen, Per L. Poulsen
Diabetes, Obesity and Metabolism.2024; 26(5): 1624. CrossRef
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
Reviews in Endocrine and Metabolic Disorders.2024; 25(4): 651. CrossRef
The Current Landscape of Pharmacotherapies for Sarcopenia
Gulistan Bahat, Serdar Ozkok
Drugs & Aging.2024; 41(2): 83. CrossRef
Role of endogenous GLP‐1 on arterial stiffness and renal haemodynamics following bariatric surgery
D. Moriconi, R. M. Bruno, E. Rebelos, S. Armenia, S. Baldi, L. Bonvicini, S. Taddei, M. Nannipieri
European Journal of Clinical Investigation.2024;[Epub] CrossRef
Vascular Aging: Assessment and Intervention
Ao Li, Jinhua Yan, Ya Zhao, Zhenping Yu, Shane Tian, Abdul Haseeb Khan, Yuanzheng Zhu, Andong Wu, Cuntai Zhang, Xiao-Li Tian
Clinical Interventions in Aging.2023; Volume 18: 1373. CrossRef
The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
Maja Preložnik Navodnik, Andrej Janež, Ivan Žuran
Pharmaceutics.2023; 15(7): 1945. CrossRef
Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment
Christian Salom Vendrell, Elisa García Tercero, Juan Bautista Moro Hernández, Bernardo Abel Cedeno-Veloz
Nutrients.2023; 15(19): 4149. CrossRef
Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
Frontiers in Endocrinology.2023;[Epub] CrossRef
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Sydney S. Wilbon, Mikhail G. Kolonin
Cells.2023; 13(1): 65. CrossRef
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
Medicines.2022; 9(9): 47. CrossRef
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-H
Journal of Clinical Medicine.2022; 12(1): 145. CrossRef
The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
Elena Massimino, Anna Izzo, Gabriele Riccardi, Giuseppe Della Pepa
Cells.2021; 10(8): 1958. CrossRef
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Xueli Zhang, Yi Zhao, Shuobing Chen, Hua Shao
Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1368. CrossRef
Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
Sofia Antoniou, Katerina K K Naka, Marios Papadakis, Aris Bechlioulis, Agathocles Tsatsoulis, Lampros K Michalis, Stelios Tigas
World Journal of Diabetes.2021; 12(11): 1856. CrossRef
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinology and Metabolism.2019; 34(3): 247. CrossRef
The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
Journal of Diabetes and its Complications.2018; 32(8): 759. CrossRef
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Konstantinos Batzias, Alexios S. Antonopoulos, Evangelos Oikonomou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Chara-Vasiliki Mistakidi, Marina Noutsou, Niki Katsiki, Periklis Karopoulos, Georgios Charalambous, Anastasia Thanopoulou, N
Journal of Diabetes Research.2018; 2018: 1. CrossRef
Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido, Ó. Lorenzo
Cardiovascular Diabetology.2017;[Epub] CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
Dong-Mee Lim, Keun-Young Park, Won-Min Hwang, Ju-Young Kim, Byung-Joon Kim
Experimental and Therapeutic Medicine.2017; 13(5): 2558. CrossRef
Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
Qiuhe Ji
Clinical Therapeutics.2017; 39(6): 1244. CrossRef
Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, Óscar Escribano
International Journal of Endocrinology.2016; 2016: 1. CrossRef

Endocrine Research
Omega-3 Polyunsaturated Fatty Acids May Attenuate Streptozotocin-Induced Pancreatic β-Cell Death via Autophagy Activation in Fat1 Transgenic Mice: Won-Min Hwang, Dong-Ho Bak, Dong Ho Kim, Ju Young Hong, Seung-Yun Han, Keun-Young Park, Kyu Lim, Dong-Mee Lim, Jae Gu Kang; Endocrinol Metab. 2015;30(4):569-575. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.569

4,908 View
45 Download
19 Web of Science
21 Crossref

Abstract PDF PubReader

Background

Inflammatory factors and β-cell dysfunction due to high-fat diets aggravate chronic diseases and their complications. However, omega-3 dietary fats have anti-inflammatory effects, and the involvement of autophagy in the etiology of diabetes has been reported. Therefore, we examined the protective effects of autophagy on diabetes using fat-1 transgenic mice with omega-3 self-synthesis capability.

Methods

Streptozotocin (STZ) administration induced β-cell dysfunction in mice; blood glucose levels and water consumption were subsequently measured. Using hematoxylin and eosin (H&E) and Masson's trichrome staining, we quantitatively assessed STZ-induced changes in the number, mass, and fibrosis of pancreatic islets in fat-1 and control mice. We identified the microtubule-associated protein 1A/1B light chain 3-immunoreactive puncta in β-cells and quantified p62 levels in the pancreas of fat-1 and control mice.

Results

STZ-induced diabetic phenotypes, including hyperglycemia and polydipsia, were attenuated in fat-1 mice. Histological determination using H&E and Masson's trichrome staining revealed the protective effects of the fat-1 expression on cell death and the scarring of pancreatic islets after STZ injection. In the β-cells of control mice, autophagy was abruptly activated after STZ treatment. Basal autophagy levels were elevated in fat-1 mice β-cells, and this persisted after STZ treatment. Together with autophagosome detection, these results revealed that n-3 polyunsaturated fatty acid (PUFA) enrichment might partly prevent the STZ-related pancreatic islet damage by upregulating the basal activity of autophagy and improving autophagic flux disturbance.

Conclusion

Fat-1 transgenic mice with a n-3 PUFA self-synthesis capability exert protective effects against STZ-induced β-cell death by activating autophagy in β-cells.

Citations

Citations to this article as recorded by

Autophagy and the pancreas: Healthy and disease states
Zixian Zhou, Pengcheng Zhang, Juan Li, Jiaqi Yao, Yuhong Jiang, Meihua Wan, Wenfu Tang, Ling Liu
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Association of erythrocyte fatty acid compositions with the risk of pancreatic cancer: A case–control study
Yongjin Wang, Gangcheng Wu, Yandan Wang, Feng Xiao, Hongming Yin, Le Yu, Qayyum Shehzad, Hui Zhang, Qingzhe Jin, Xingguo Wang
Lipids.2024;[Epub] CrossRef
Mitochondrial Dysfunction and Mitophagy in Type 2 Diabetes: Pathophysiology and Therapeutic Targets
Nadezda Apostolova, Teresa Vezza, Jordi Muntane, Milagros Rocha, Víctor M. Víctor
Antioxidants & Redox Signaling.2023; 39(4-6): 278. CrossRef
β Cell and Autophagy: What Do We Know?
Hamid-Reza Mohammadi-Motlagh, Mona Sadeghalvad, Niloofar Yavari, Rosita Primavera, Setareh Soltani, Shashank Chetty, Abantika Ganguly, Shobha Regmi, Tina Fløyel, Simranjeet Kaur, Aashiq H. Mirza, Avnesh S. Thakor, Flemming Pociot, Reza Yarani
Biomolecules.2023; 13(4): 649. CrossRef
The ameliorating effects of mesenchymal stem cells compared to α‐tocopherol on apoptosis and autophagy in streptozotocin‐induced diabetic rats: Implication of PI3K/Akt signaling pathway and entero‐insular axis
Heba A. Mubarak, Manal M. Kamal, Yossra Mahmoud, Fatma S. Abd‐Elsamea, Eman Abdelbary, Marwa G. Gamea, Reham I. El‐Mahdy
Journal of Cellular Biochemistry.2023; 124(11): 1705. CrossRef
Nutraceuticals as Modulators of Autophagy: Relevance in Parkinson’s Disease
Michał Rakowski, Szymon Porębski, Agnieszka Grzelak
International Journal of Molecular Sciences.2022; 23(7): 3625. CrossRef
High n-3 fatty acids counteract hyperglycemia-induced insulin resistance in fat-1 miceviapre-adipocyte NLRP3 inflammasome inhibition
Qingyao Yu, Tiantian Wang, Feng Wang, Yong Yang, Canxia He, Wenge Yang, JinJie Zhang, Zuquan Zou
Food & Function.2021; 12(1): 230. CrossRef
Metabolic and Metabolomic Insights Regarding the Omega-3 PUFAs Intake in Type 1 Diabetes Mellitus
Carmen Purdel, Anca Ungurianu, Denisa Margina
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Effects of the linoleic acid/docosahexaenoic acid ratio and concentration inducing autophagy in Raw264.7 cells against Staphylococcus aureus
Li-Ying Xu, Min Mu, Man-Li Wang, Jin-Cheng Liu, Yuan-Jie Zhou, Jing Wu, Bing-You Jiang, Ming-Gong Chen, Dong Hu, Xing-Rong Tao
Journal of Clinical Biochemistry and Nutrition.2020; 67(2): 146. CrossRef
Free fatty acid receptor 3 differentially contributes to β-cell compensation under high-fat diet and streptozotocin stress
Medha Priyadarshini, Connor Cole, Gautham Oroskar, Anton E. Ludvik, Barton Wicksteed, Congcong He, Brian T. Layden
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.2020; 318(4): R691. CrossRef
Mitochondria and T2D: Role of Autophagy, ER Stress, and Inflammasome
Milagros Rocha, Nadezda Apostolova, Ruben Diaz-Rua, Jordi Muntane, Victor M. Victor
Trends in Endocrinology & Metabolism.2020; 31(10): 725. CrossRef
Omega-3 Polyunsaturated Fatty Acids Prevent Toxoplasma gondii Infection by Inducing Autophagy via AMPK Activation
Jae-Won Choi, Jina Lee, Jae-Hyung Lee, Byung-Joon Park, Eun Jin Lee, Soyeon Shin, Guang-Ho Cha, Young-Ha Lee, Kyu Lim, Jae-Min Yuk
Nutrients.2019; 11(9): 2137. CrossRef
Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction
Yu-Xue Xu, Caoxin Huang, Minyi Liu, Ningning Chen, Wenting Chen, Chen Yang, Yan Zhao, Xuejun Li, Junguo Duan, Suhuan Liu, Shuyu Yang
Experimental Cell Research.2018; 364(2): 152. CrossRef
Autophagy in Metabolic Age-Related Human Diseases
Manon Moulis, Cecile Vindis
Cells.2018; 7(10): 149. CrossRef
A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats
Abraham A.A. Osinubi, Leke Jacob Medubi, Edidiong N. Akang, Lawal K. Sodiq, Titilola A. Samuel, Taiwo Kusemiju, James Osolu, Danladi Madu, Olufemi Fasanmade
Toxicology Reports.2018; 5: 832. CrossRef
β-Cell Autophagy in Diabetes Pathogenesis
Michelle R Marasco, Amelia K Linnemann
Endocrinology.2018; 159(5): 2127. CrossRef
Endogenous synthesis of n-3 polyunsaturated fatty acids in fat-1 transgenic mice ameliorates streptozocin-induced diabetic nephropathy
Yuan-Ming Zhang, Xiao-Hong Zhang, Pan Zhu, Rong-Hui Tan, Jin-Shun Zhao, Feng Wang, Jin-Jie Zhang, Wang Yan, Yang Xi, Jian-Bo Wan, Jing-Xuan Kang, Zu-Quan Zou, Shi-Zhong Bu
Journal of Functional Foods.2018; 45: 427. CrossRef
PHLPP: a putative cellular target during insulin resistance and type 2 diabetes
Alpana Mathur, Vivek Kumar Pandey, Poonam Kakkar
Journal of Endocrinology.2017; 233(3): R185. CrossRef
Coenzyme Q10 ameliorates cerebral ischemia reperfusion injury in hyperglycemic rats
Cui-Jie Lu, Yong-Zhen Guo, Yang Zhang, Lan Yang, Yue Chang, Jing-Wen Zhang, Li Jing, Jian-Zhong Zhang
Pathology - Research and Practice.2017; 213(9): 1191. CrossRef
Changes in pancreatic histology, insulin secretion and oxidative status in diabetic rats following treatment with Ficus deltoidea and vitexin
Samsulrizal Nurdiana, Yong Meng Goh, Hafandi Ahmad, Sulaiman Md Dom, Nur Syimal’ain Azmi, Noor Syaffinaz Noor Mohamad Zin, Mahdi Ebrahimi
BMC Complementary and Alternative Medicine.2017;[Epub] CrossRef
Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea
H.-S. Kim, H. Kim, Y. J. Jeong, S. J. Yang, S. J. Baik, H. Lee, S.-H. Lee, J. H. Cho, I.-Y. Choi, H. W. Yim, K.-H. Yoon
Journal of Clinical Pharmacy and Therapeutics.2016; 41(5): 508. CrossRef

Author index